trending Market Intelligence /marketintelligence/en/news-insights/trending/0f5S-CgG13rwIb3DhePepg2 content esgSubNav
In This List

US FDA approves Bristol-Myers' Opdivo to treat bladder cancer

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


US FDA approves Bristol-Myers' Opdivo to treat bladder cancer

Bristol-Myers Squibb Co. received U.S. FDA approval for Opdivo as an intravenous treatment for a type of bladder cancer.

The drug will be used to treat patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with such chemotherapy.